secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001477932-25-002406
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioNexus Gene Lab announces 1-for-10 reverse stock split effective April 7, 2025 to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-10 ratio; effective 12:01 a.m. ET on April 7, 2025.
- Company aims to cure Nasdaq bid price deficiency; must close above $1.00 for 10 consecutive days by May 1, 2025.
- No fractional shares issued; shareholders receive cash in lieu based on April 4, 2025 closing price.
- New CUSIP number 090628306; ticker symbol BGLC unchanged.
- Shareholders holding electronically or in brokerage accounts adjusted automatically; physical certificate holders to receive instructions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225002406/0001477932-25-002406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225002406/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-002406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer